Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset....
Hence then, the article about boehringer ingelheim and simcere partner to advance a dual target antibody treatment to address unmet needs in inflammatory bowel disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease )
Also on site :
- 'Real Housewives of Salt Lake City' Star Angie Katsanevas & Husband Shawn Trujillo Split After 27 Years of Marriage
- U.S. military launches 10th straight night of airstrikes on Iran as Houthi allies threaten Red Sea, but glimmers of hope appear on diplomatic front
- T.J. Maxx's Beautiful Linen Dining Chair Sets Has Shoppers Racing to Buy Them Before They're Gone for Good